Cancer Diagnostics Market 2019 Segments, Trends, Share and Forecast Growth

The Global Cancer Diagnostics Market is expected to reach $13.1 Billion, at a CAGR of 12.9%

Technological advancements in various fields such as biomarkers, imaging, biopsy, endoscopy; growing number of cancer cases, the rapid rise in geriatric population, awareness initiatives by governments, and increasing government funding are major factors driving the Cancer Diagnostics Market growth.

However, high capital investment and low benefit-cost ratio of biomarkers and dearth of skilled professionals pose restraints to the growth of this market. Improving healthcare infrastructure in emerging countries and the growing demand for companion diagnostics offer growth opportunities for this market.

Download PDF (Cancer Diagnostics): https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=186559121

Cancer Diagnostics Market segmentation:

· based on technology.

· based on application.

· based on regions.

Cancer Diagnostics Market Key Drivers:

· Rising Prevalence of Cancer

· Technological Advancements

· Initiatives Undertaken by Governments and Global Health Organizations to Spread Awareness About Cancer

· Growth in the Number of Private Diagnostic Centers

· Launch of New Flow Cytometry Reagents for Diagnostics and Drug Discovery

Cancer Diagnostics Market Opportunities:

· Personalized Medicine

· Development of Mass Cytometry and the Combination of Cell-And Bead-Based Flow Cytometry Technologies

· Companion Diagnostics

· Improving Healthcare Infrastructure in Emerging Markets

· Miniaturized and Technologically Advanced Devices

The Major Players Operating in the Cancer Diagnostics Market:

Some of the major players in the Global Market include Agilent Technologies, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Illumina, Inc. (Denmark), Becton, Dickinson and Company (U.S.), GE Healthcare (U.K.), QIAGEN N.V. (Netherlands), Abbott Laboratories, Inc. (U.S.), Roche Diagnostics (Switzerland), Siemens Healthcare (Germany), Philips Healthcare (U.K.), and C.R. Bard, Inc. (U.S.), among others.

Geographical Detailed Analysis for Cancer Diagnostics Market:

Based on the region, the market is divided into North America, Europe, Asia, and Rest of the World (Row). Rest of the World comprises Latin America, Pacific countries, and the Middle East and Africa. North America is expected to account for the largest share in the Cancer Diagnostics Market, followed by Europe and Asia.

However, the Asian market is slated to grow at the highest CAGR in the coming five years and serves as a revenue pocket for the companies operating in the Cancer Diagnostics Market.

Read More in Detailed (Cancer Diagnostics):

https://www.marketsandmarkets.com/Market-Reports/cancer-diagnostics-market-186559121.html

Cancer Diagnostics Market Size, Share, Outlook, Industry Analysis Report 2018

The Cancer Diagnostics Market is expected to reach around $13.1 Billion by 2020 with a CAGR of 12.9% from 2015 to 2020.

According to a new market research report “Cancer Diagnostics Market by Technology (ELISA, ELFA, PCR, NGS, Immunohistochemistry, Microarray, Imaging (MRI, CT, PET, Ultrasound, Mammography), Biopsy), Application (Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma) — Forecast to 2020”, published by MarketsandMarkets.

Browse 89 market data tables and 37 figures spread through 197 pages and in-depth TOC on “Cancer Diagnostics Market”

http://www.marketsandmarkets.com/Market-Reports/cancer-diagnostics-market-186559121.html

This report studies the global cancer diagnostics market for the forecast period of 2015 to 2020. This market is expected to reach $13.1 Billion by 2020 from $7.1 Billion in 2015, and is poised to grow at a CAGR of 12.9% during the forecast period.

The global cancer diagnostics market is segmented on the basis of technology, application, and region. Based on technology, the cancer diagnostics market is categorized into platform-based and instrument-based. The instrument-based segment is expected to account for a major share of the cancer diagnostics market, by product, in 2015.

Based on the application, the cancer diagnostics market is segmented into lung cancer, breast cancer, colorectal cancer, melanoma, and others. Breast cancer application is expected to account for a major share of the cancer diagnostics market, by application in 2015.

Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownload.asp?id=186559121

On the basis of region, the market is divided into North America, Europe, Asia, and Rest of the World (RoW). Rest of the World comprises Latin America, Pacific countries, and Middle East and Africa. North America is expected to account for the largest share in the cancer diagnostics market, followed by Europe and Asia. However, the Asian market is slated to grow at the highest CAGR in the coming five years and serves as a revenue pocket for the companies operating in the cancer diagnostics market.

The global cancer diagnostics market is witnessing a rapid transformation owing to several technological advancements in diagnostic platforms. Moreover, the market has seen the advent of hybrid imaging instruments with enhanced accuracy, such as PET/CT and SPECT/CT. These advancements have augmented the growth of the cancer diagnostics market. However, shortage of trained and skilled personnel poses as a restraint to the market growth of cancer diagnostics. The rise in aging population and increasing cancer cases are likely to create a huge opportunity for cancer diagnostics.

Inquiry on this Report:http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=186559121

Some of the major players in the global Cancer Diagnostics System Marketinclude Agilent Technologies, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Illumina, Inc. (Denmark), Becton, Dickinson and Company (U.S.), GE Healthcare (U.K.), QIAGEN N.V. (Netherlands), Abbott Laboratories, Inc. (U.S.), Roche Diagnostics (Switzerland), Siemens Healthcare (Germany), Philips Healthcare (U.K.), and C.R. Bard, Inc. (U.S.), among others.

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their pain points around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model — GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledge Store” connects over 200,000 markets and entire value chains for a deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact Us:
 Mr. Shelly Singh
 MarketsandMarkets™ INC.
 630 Dundee Road
 Suite 430
 Northbrook, IL 60062
 USA: +1–888–600–6441
 Email: sales@marketsandmarkets.com